Georgia's Online Cancer Information Center

Unknown Primary Clinical Trials in Georgia

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.
Cancer Type = Unknown Primary
Cancer Type = Unknown Primary
There are currently 212 active Unknown Primary clinical trials in Georgia.
1.
(Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05186753
Protocol IDs
CGT9486-21-202
NCI-2022-01167
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
2.
6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer
Cancer Type
Unknown Primary
NCT ID
NCT03800693
Protocol IDs
Winship4468-18
NCI-2018-02241
IRB00106610
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
3.
A Clinical Study of V940 Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT05933577
Protocol IDs
V940-001
NCI-2023-05647
2023-503652-27-00
V940-001
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
4.
A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05323253
Protocol IDs
CTP-SCC-03
NCI-2022-10859
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
5.
NCORP Trial
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma
Cancer Type
Melanoma, Unknown Primary
NCT ID
NCT02339571
Protocol IDs
EA6141
NCI-2014-02674
Treatment Sites (5)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
6.
A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05482971
Protocol IDs
EXCEED ET / A22-301
NCI-2023-00605
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
7.
A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE
Cancer Type
Unknown Primary
NCT ID
NCT05171075
Protocol IDs
ANT-008
NCI-2022-08854
2021-003085-12
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
8.
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05459129
Protocol IDs
CO43613
NCI-2022-06114
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
11.
A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery
Cancer Type
Unknown Primary
NCT ID
NCT04195399
Protocol IDs
ARST1921
ARST1921
NCI-2019-07498
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
12.
A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT
Cancer Type
Germ Cell Tumor, Gestational trophoblastic disease, Testicular Cancer, Unknown Primary
NCT ID
NCT04684368
Protocol IDs
ACNS2021
ACNS2021
NCI-2020-13175
13.
A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
Cancer Type
Ovarian Cancer, Solid Tumor, Unknown Primary, Uterine Cancer
NCT ID
NCT05548296
Protocol IDs
ACR-368-201 (GOG 3082)
NCI-2022-10629
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
14.
A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03571568
Protocol IDs
17-BI1206-02
NCI-2018-02697
Treatment Sites (1)
15.
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05879744
Protocol IDs
CLN-978-001
NCI-2023-04426
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
16.
A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT
Cancer Type
Brain Tumor, Unknown Primary, Wilms Tumor
NCT ID
NCT04322318
Protocol IDs
AREN1921
AREN1921
NCI-2020-01561
Treatment Sites (1)
17.
A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT04104776
Protocol IDs
0209-01
NCI-2020-01007
20.
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
Cancer Type
Unknown Primary
NCT ID
NCT05263999
Protocol IDs
EQ-100-02
NCI-2022-02430
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
21.
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05241834
Protocol IDs
LOXO-NGR-21001
NCI-2022-01823
J3T-OX-JZTA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
22.
A Study of LOXO-435 in Participants With Cancer With a Change in a Gene Called FGFR3
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05614739
Protocol IDs
LOXO-FG3-22001
NCI-2023-00367
022-502755-59-00
2022-502755-59-00
J4G-OX-JZVA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
23.
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors
Cancer Type
Breast Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05307705
Protocol IDs
LOXO-PIK-21001
NCI-2022-04290
2022-000175-40
J4C-OX-JZUA
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
24.
A Study of NKT2152, a HIF2a Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05119335
Protocol IDs
NKT2152-101
NCI-2021-13434
25.
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05787587
Protocol IDs
IDE161-001
NCI-2023-03139
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
27.
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
NCT ID
NCT05487170
Protocol IDs
RNK05047-01
NCI-2022-09252
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
28.
A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)
Cancer Type
Brain & Spinal Cord Tumor, Colon/Rectal Cancer, Head and Neck Cancer, Lung Cancer, Neuroendocrine Tumor, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT03157128
Protocol IDs
LOXO-RET-17001
NCI-2017-00976
2017-000800-59
Treatment Sites (1)
29.
A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04919512
Protocol IDs
CR109044
NCI-2022-05645
17000139BLC2002
2020-005565-13
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
30.
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT05714202
Protocol IDs
CR109223
NCI-2023-05193
17000139BLC3002
2020-004506-64
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
31.
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04658862
Protocol IDs
CR108917
NCI-2021-10015
17000139BLC3001
2020-002620-36
32.
A Study of Tolinapant in Combination With Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma (R/R PTCL)
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05403450
Protocol IDs
ASTX660-03
NCI-2022-10432
2021-005338-40
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
33.
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05132582
Protocol IDs
SGNTUC-028
NCI-2022-00541
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
34.
A Study of XMT-1660 in Participants With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05377996
Protocol IDs
MER-XMT-1660-1
NCI-2022-04696
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
35.
A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04546399
Protocol IDs
AALL1821
AALL1821
NCI-2020-06813
Treatment Sites (1)
36.
A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT04994132
Protocol IDs
ARST2031
ARST2031
NCI-2021-06711
37.
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05675410
Protocol IDs
AHOD2131
AHOD2131
NCI-2022-10845
38.
A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT04576117
Protocol IDs
ACNS1931
ACNS1931
NCI-2020-07549
39.
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05581004
Protocol IDs
GO43860
NCI-2022-08852
2021-006708-34
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
40.
A Study to Learn More About the Health of Persons with Down Syndrome After Treatment for Acute Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT05702645
Protocol IDs
ALTE22C1
ALTE22C1
ALTE22C1
NCI-2022-09410
41.
A Study to See if Memantine Protects the Brain during Radiation Therapy Treatment for Primary Central Nervous System Tumors
Cancer Type
Unknown Primary
NCT ID
NCT04939597
Protocol IDs
ACCL2031
ACCL2031
COG-ACCL2031
NCI-2020-07502
42.
Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04883437
Protocol IDs
WINSHIP5186-20
NCI-2021-00894
STUDY00002247
43.
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05653271
Protocol IDs
ACE1831-001
NCI-2023-03335
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
44.
Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary, Urethral Cancer
NCT ID
NCT02122172
Protocol IDs
IRB13-0540
NCI-2014-00859
13-0540
45.
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05952557
Protocol IDs
D8535C00001
NCI-2023-06834
2023-504031-41-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
46.
An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05011058
Protocol IDs
VT3996-202
NCI-2021-09770
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
47.
ARX517 as Monotherapy and in Combination Regimens in Subjects With Metastatic Castration-resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04662580
Protocol IDs
ARX517-2011
NCI-2021-03637
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
48.
ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03769506
Protocol IDs
ASP-1929-301
NCI-2019-01324
49.
Biomarker-Driven Radiation Therapy Dose Reduction after Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT05387915
Protocol IDs
WINSHIP5566-22
NCI-2022-02855
STUDY00004187
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
50.
NCORP Trial
Biospecimen Collection in Identifying Genetic Changes in Patients with Breast, Prostate, Colorectal, Liver, or Kidney Cancer or Multiple Myeloma Undergoing Surgery
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Kidney Cancer, Liver Cancer / Hepatoblastoma, Multiple Myeloma, Plasma cell neoplasm, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT04955808
Protocol IDs
DCP-002
DCP-002
DCP-002
NCI-2017-01572
Treatment Sites (1)
51.
Brentuximab Vedotin and Nivolumab for the Treatment of Relapsed/Refractory Classic Hodgkin Lymphoma Previously Treated with Brentuximab Vedotin or Checkpoint Inhibitors
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT05039073
Protocol IDs
WINSHIP5260-21
NCI-2021-01655
STUDY00002348
Treatment Sites (2)
52.
Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Cancer Type
Hematopoietic Malignancies, Hodgkin Lymphoma, Lymphoma, Unknown Primary
NCT ID
NCT01896999
Protocol IDs
NCI-2013-01275
U10CA021115
E4412
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
53.
Cabozantinib and Isotretinoin in Treating Children with Relapsed or Refractory Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT03611595
Protocol IDs
171971
NCI-2018-02497
54.
Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04878029
Protocol IDs
WINSHIP5259-21
NCI-2021-01365
STUDY00002329
55.
Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT03541902
Protocol IDs
2017-0725
NCI-2018-01041
56.
CAR-T Long Term Follow Up (LTFU) Study
Cancer Type
Unknown Primary
NCT ID
NCT02445222
Protocol IDs
CCTL019A2205B
NCI-2015-01238
2014-001673-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
57.
Cemiplimab before and after Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT04428671
Protocol IDs
Winship4851-19
NCI-2019-07373
IRB00115160
58.
Chemotherapy for the Treatment of Patients with Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT05304585
Protocol IDs
ARST2032
ARST2032
NCI-2022-01012
59.
Clinical Utility of FES F18 PET/CT in Metastatic Breast Cancer Patients
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05068726
Protocol IDs
GE-280-401
NCI-2022-08763
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
60.
Collecting Blood Samples from Patients with and without Cancer to Evaluate Tests for Early Cancer Detection
Cancer Type
Breast Cancer, Head and Neck Cancer, Hematopoietic Malignancies, Kidney Cancer, Leukemia, Melanoma, Sarcoma, Solid Tumor, Thyroid Cancer, Unknown Primary
NCT ID
NCT05334069
Protocol IDs
A212102
A212102
A212102
NCI-2022-02477
Treatment Sites (1)
61.
Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT02997228
Protocol IDs
NRG-GI004
NRG-GI004
NCI-2016-01961
NRG-GI004/S1610
Treatment Sites (1)
Southern Regional Medical Center
Riverdale
Stephen Cohen, MD
770-997-1975
62.
Combining Radiation Therapy with Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05721755
Protocol IDs
EA3211
EA3211
NCI-2022-10141
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
63.
Comparing Cisplatin Every Three Weeks to Cisplatin Weekly When Combined with Radiation for Patients with Advanced Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT05050162
Protocol IDs
NRG-HN009
NRG-HN009
NCI-2021-08925
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
64.
NCORP Trial
Comparing Overall Survival using Markers to Direct Cancer Monitoring versus Usual Monitoring in Patients with Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03723928
Protocol IDs
S1703
S1703
SWOG-S1703
NCI-2018-00090
Treatment Sites (1)
65.
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
Cancer Type
Esophogeal Cancer, Unknown Primary
NCT ID
NCT03801876
Protocol IDs
NRG-GI006
NRG-GI006
NCI-2018-03378
66.
Comparing the Addition of Radiation either before or after Surgery for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT05438212
Protocol IDs
NRG-BN012
NRG-BN012
NCI-2022-04804
Treatment Sites (1)
67.
Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03678025
Protocol IDs
S1802
S1802
NCI-2018-01738
Treatment Sites (2)
68.
Comparing Two Methods to Follow Patients with Pancreatic Cysts
Cancer Type
Unknown Primary
NCT ID
NCT04239573
Protocol IDs
EA2185
EA2185
ECOG-ACRIN-EA2185
NCI-2019-04790
69.
Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial
Cancer Type
Gallbladder Cancer, Unknown Primary
NCT ID
NCT04559139
Protocol IDs
EA2197
EA2197
NCI-2020-05162
70.
Curcumin in Treating HIV Infected and Uninfected Women with High Grade Cervical Squamous Intraepithelial Neoplasia
Cancer Type
Unknown Primary
NCT ID
NCT02944578
Protocol IDs
EU2971-15
NCI-2016-01405
IRB00079183
Treatment Sites (3)
71.
CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT03904862
Protocol IDs
PBTC-053
PBTC-053
NCI-2019-00180
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
72.
DALY 2.0 USA/ MB-CART2019.1 for DLBCL
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04792489
Protocol IDs
M-2018-344
NCI-2021-08357
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
73.
Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT05555732
Protocol IDs
DS1062-A-U303
NCI-2023-06122
2022-500802-16-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
74.
De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03952585
Protocol IDs
NRG-HN005
NRG-HN005
NCI-2019-03015
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
75.
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04567420
Protocol IDs
DARE
NCI-2021-03770
76.
Dose-Escalation and Dose-Expansion Study of ZX-4081 in Patients With Advanced Solid Tumors
Cancer Type
Breast Cancer, Colon/Rectal Cancer, Liver Cancer / Hepatoblastoma, Lung Cancer, Melanoma, Ovarian Cancer, Unknown Primary
NCT ID
NCT05118841
Protocol IDs
ZX-4081
NCI-2022-02249
77.
NCORP Trial
Duloxetine to Prevent Oxaliplatin-Induced Peripheral Neuropathy
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT04137107
Protocol IDs
A221805
A221805
A221805
NCI-2019-04727
78.
Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04652960
Protocol IDs
10347
10347
NCI-2020-11641
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
79.
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients with Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04890236
Protocol IDs
Winship5085-20
NCI-2020-06380
STUDY00001001
80.
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients
Cancer Type
Anal Cancer, Unknown Primary
NCT ID
NCT04444921
Protocol IDs
EA2176
EA2176
NCI-2020-04334
81.
Educational Interview in Improving Health Literacy in African-American Participants with Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03322891
Protocol IDs
HU-HEALTHLITERACY
NCI-2018-00842
IRB00091879
IRB00085616
Treatment Sites (4)
82.
Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05626322
Protocol IDs
C4971003
NCI-2023-00764
2022-50242721-00
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
83.
ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study
Cancer Type
Unknown Primary
NCT ID
NCT04620239
Protocol IDs
CLIN2001 UCM301
NCI-2021-07136
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
84.
Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT04223856
Protocol IDs
SGN22E-003
NCI-2020-01070
2019-004542-15
MK-3475-A39
Treatment Sites (1)
85.
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05696626
Protocol IDs
SMX 22-002
NCI-2023-09871
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
86.
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05714345
Protocol IDs
ALLO-647-201
NCI-2023-02445
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
87.
Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03328104
Protocol IDs
AflacLL1602
NCI-2017-01717
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
88.
Fatigue Assessment in Patients with Breast Cancer Undergoing Chemotherapy, Surgery, or Radiation Therapy
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT02759549
Protocol IDs
WCI1651-09
NCI-2016-00824
IRB00028295
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
89.
NCORP Trial
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04960787
Protocol IDs
S1912CD
S1912CD
SWOG-S1912CD
NCI-2021-00579
Treatment Sites (1)
90.
First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04761601
Protocol IDs
UCT01097-001
NCI-2021-02135
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
91.
First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05103046
Protocol IDs
UCT03008-001
NCI-2021-14000
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
92.
Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET/CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT03762759
Protocol IDs
RAD4516-18
NCI-2018-02702
IRB00106863
Treatment Sites (3)
93.
Gene Expression in Blood Samples from High-Risk Postmenopausal Women Who Received Treatment on Breast Cancer Prevention Clinical Trials NSABP-P-1 or NSABP-P-2
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT00967239
Protocol IDs
MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I
94.
Genetic Testing in Guiding Treatment for Patients with Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT03994796
Protocol IDs
A071701
A071701
NCI-2019-00744
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
95.
Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03765736
Protocol IDs
ACCRU-GI-1611
NCI-2018-02862
96.
NCORP Trial NCI Priority
Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02194738
Protocol IDs
NCI-2014-01509
A151216
U10CA180821
U10CA031946
Treatment Sites (28)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
Atlanta Cancer Care - Conyers
Conyers
404-303-3355
Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041
Atlanta Cancer Care - Decatur
Decatur
404-303-3355
Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069
Atlanta Cancer Care - Tower
Atlanta
404-303-3355
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Cancer Center at DeKalb Medical Center
Decatur
Cathy Comer
404-501-7789
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle
Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242
Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152
Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555
Gwinnett Medical Center
Lawrenceville
404-851-2340
Harbin Clinic Cancer Center
Rome
Dilawar Khan, MD
706-528-9110
Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
Pearlman Cancer Center at South Georgia Medical Center
Valdosta
Jeffrey Hoy
229-259-4628
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
97.
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT05553639
Protocol IDs
H-300-001
NCI-2023-02949
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
98.
Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05659381
Protocol IDs
GOG-3068
NCI-2023-08813
217908
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
99.
Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03153202
Protocol IDs
17-0554
NCI-2017-01538
100.
IMGN853 With Carboplatin in Second-line Treatment of FRa Expressing, Platinum-sensitive Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05456685
Protocol IDs
IMGN853-0420
NCI-2022-09869
2022-002034-14
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
101.
Immune Checkpoint Inhibitors with or without Propranolol Hydrochloride for the Treatment of Urothelial Cancer
Cancer Type
Unknown Primary
NCT ID
NCT04848519
Protocol IDs
WINSHIP5200-20
NCI-2021-00437
102.
Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT03739814
Protocol IDs
A041703
A041703
NCI-2018-02484
103.
Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT02981628
Protocol IDs
AALL1621
AALL1621
NCI-2016-01494
AALL1621
Treatment Sites (1)
104.
Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis
Cancer Type
Hematopoietic Malignancies, Unknown Primary
NCT ID
NCT04754945
Protocol IDs
Winship5086-20
NCI-2020-06548
105.
KZR-261 in Subjects With Advanced Solid Malignancies
Cancer Type
Colon/Rectal Cancer, Eye Cancer, Melanoma, Prostate Cancer , Solid Tumor, Unknown Primary
NCT ID
NCT05047536
Protocol IDs
KZR-261-101
NCI-2022-01096
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
107.
Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04393350
Protocol IDs
Winship4955-20
NCI-2020-01064
108.
NCORP Trial
Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04095364
Protocol IDs
NRG-GY019
NRG-GY019
NCI-2019-01460
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
109.
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Cancer Type
Unknown Primary
NCT ID
NCT03435796
Protocol IDs
GC-LTFU-001
NCI-2018-00957
U1111-1206-8250
2017-001465-24
110.
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Cancer Type
Unknown Primary
NCT ID
NCT03486873
Protocol IDs
3475-587
2017-004417-42
NCI-2018-01717
MK-3475-587
Treatment Sites (10)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
111.
Low Dose Y90 Microspheres for the Planning of Radioembolization Therapy in Patients with Stage A-C Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCT ID
NCT04172714
Protocol IDs
RAD4784-19
NCI-2019-06505
IRB00112192
Treatment Sites (3)
Emory Clinic
Atlanta
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
112.
Making Informed Choices on Incorporating Chemoprevention into Care (MiCHOICE)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04496739
Protocol IDs
S1904
S1904
SWOG-S1904
NCI-2019-08755
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
113.
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03053193
Protocol IDs
FLEX Registry
NCI-2018-02995
Treatment Sites (4)
Piedmont Cancer Institute - Atlanta
Atlanta
Katie Adams
678-298-3238
Piedmont Cancer Institute - Fayetteville
Fayetteville
678-298-3238
Piedmont Cancer Institute - Newnan
Newnan
Katie Adams
678-298-3238
Piedmont Cancer Institute - Stockbridge
Stockbridge
Katie Adams
678-298-3238
114.
Message-Based Communication Outreach Intervention in Engaging Ovarian Cancer Survivors and Relatives to Consider Genetic Screening Services
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT04927013
Protocol IDs
RSPH4984-20
NCI-2020-02281
STUDY00000224
115.
Metformin for the Prevention of Oral Cancer in Patients with Oral Leukoplakia or Erythroplakia
Cancer Type
Unknown Primary
NCT ID
NCT05237960
Protocol IDs
Pending12
UAZ21-07-01
NCI-2022-00596
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
116.
Mindfulness-based Smoking Cessation Enhanced With Mobile Technology
Cancer Type
Unknown Primary
NCT ID
NCT04965181
Protocol IDs
R01CA237004
NCI-2021-08950
117.
Mobile Health for Adherence in Breast Cancer Patients
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT06112613
Protocol IDs
EAQ221CD
EAQ221CD
ECOG-ACRIN-EAQ221CD
NCI-2023-02646
Treatment Sites (2)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
118.
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05568472
Protocol IDs
SWOG-S2010
S2010
SWOG-S2010
NCI-2022-06902
119.
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial
Cancer Type
Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT03150914
Protocol IDs
RLDC5713
NCI-2019-08422
U01HL131755-01
Treatment Sites (1)
120.
Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT03983993
Protocol IDs
Winship4517-18
NCI-2018-02757
IRB00107377
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
121.
Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04759586
Protocol IDs
ANHL1931
ANHL1931
NCI-2021-01071
122.
NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05664217
Protocol IDs
18-255-01
NCI-2023-02609
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
123.
NCORP Trial
Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03269669
Protocol IDs
S1608
S1608
NCI-2017-00009
S1608
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
124.
NCORP Trial
Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT04181060
Protocol IDs
EA5182
EA5182
NCI-2019-07941
Treatment Sites (1)
125.
Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer
Cancer Type
Pancreatic Cancer, Unknown Primary
NCT ID
NCT04524702
Protocol IDs
Winship5079-20
NCI-2020-05417
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
126.
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT02343224
Protocol IDs
IRB00074563
Treatment Sites (1)
Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853
127.
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
Cancer Type
Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03833167
Protocol IDs
3475-630
KEYNOTE-630
2018-001974-76
NCI-2019-01629
MK-3475-630
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
129.
Pepinemab with or without Ipilimumab and/or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer
Cancer Type
Head and Neck Cancer, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03690986
Protocol IDs
Winship4402-18
NCI-2018-01263
IRB00103534
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
130.
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients with Low Testosterone
Cancer Type
Unknown Primary
NCT ID
NCT04731376
Protocol IDs
EU5097-20
NCI-2020-06998
131.
Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05037149
Protocol IDs
SRN-707-001
NCI-2022-02026
132.
Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT03785249
Protocol IDs
849-001
NCI-2019-01032
Treatment Sites (9)
Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131
Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131
133.
Phase 1a/1b Study of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Solid Tumors
Cancer Type
Brain & Spinal Cord Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Solid Tumor, Unknown Primary
NCT ID
NCT05098132
Protocol IDs
STK-012-101
NCI-2022-00633
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
134.
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04964934
Protocol IDs
D8534C00001
NCI-2022-01653
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
135.
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04365374
Protocol IDs
GTM-102
NCI-2021-03480
136.
NCORP Trial
Project: Every Child for Younger Patients with Cancer
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Leukemia, Neuroendocrine Tumor, Solid Tumor, Unknown Primary
NCT ID
NCT02402244
Protocol IDs
APEC14B1
NCI-2014-02057
Treatment Sites (2)
Atrium Health Navicent
Macon
Oncology Research Nurse
4786332152
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
137.
Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04725903
Protocol IDs
RAD5131-20
NCI-2020-07113
138.
PRT3789 Monotherapy and in Combo w/Docetaxel in Participants w/Advanced or Metastatic Solid Tumors w/SMARCA4 Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05639751
Protocol IDs
PRT3789-01
NCI-2023-01949
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
139.
NCORP Trial
Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT03598257
Protocol IDs
S1706
S1706
NCI-2018-01519
Treatment Sites (1)
140.
Radioligand Therapy after PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT06105918
Protocol IDs
RAD5633-23
NCI-2023-03480
STUDY00005677
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
141.
Reaching Rural Cancer Survivors Who Smoke
Cancer Type
Unknown Primary
NCT ID
NCT05008848
Protocol IDs
A211901
A211901
A211901
NCI-2021-03543
142.
Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma
Cancer Type
Brain & Spinal Cord Tumor, Brain Tumor, Unknown Primary
NCT ID
NCT02724579
Protocol IDs
ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422
Treatment Sites (1)
143.
Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT04922307
Protocol IDs
VICCURO2114
NCI-2021-10595
144.
REFOCUS: A First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors
Cancer Type
Bile Duct Cancer, Liver Cancer / Hepatoblastoma, Solid Tumor, Unknown Primary
NCT ID
NCT04526106
Protocol IDs
RLY-4008-101
NCI-2020-06870
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
145.
Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer
Cancer Type
Liver Cancer / Hepatoblastoma, Unknown Primary
NCT ID
NCT05194293
Protocol IDs
ACCRU-GI-1920
NCI-2021-12021
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
146.
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Cancer Type
Gynecologic Cancers, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05257408
Protocol IDs
CORT125134-556
NCI-2022-07960
GOG-3073
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
147.
Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Cancer Type
Ovarian Cancer, Unknown Primary
NCT ID
NCT05998135
Protocol IDs
WINSHIP5782-22
NCI-2023-03479
STUDY00005363
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
148.
Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT03267433
Protocol IDs
EA4151
EA4151
NCI-2016-01403
EA4151
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
149.
Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation
Cancer Type
Unknown Primary
NCT ID
NCT01656603
Protocol IDs
6637-01
NCI-2016-01676
Treatment Sites (1)
Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355
150.
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early Triple Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05929768
Protocol IDs
S2212
S2212
NCI-2023-02688
151.
Smoke-Free Homes Intervention for the Prevention of Smoking
Cancer Type
Unknown Primary
NCT ID
NCT04547686
Protocol IDs
SFH-5A-RCT
NCI-2021-01784
STUDY00001085
152.
Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients with Brain Tumors
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT04908709
Protocol IDs
RAD4500-18
NCI-2018-02065
IRB00106849
153.
Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04295863
Protocol IDs
IRB19-1718
NCI-2020-13885
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
154.
Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5 or more Brain Metastases
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT03550391
Protocol IDs
CCTG CE.7
CE.7
CCTG CE.7
NCI-2018-00395
Treatment Sites (2)
155.
Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT03847519
Protocol IDs
ADXS-503-101
NCI-2019-01784
Treatment Sites (1)
156.
Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin
Cancer Type
Bladder Cancer, Unknown Primary
NCT ID
NCT04452591
Protocol IDs
CG3002S
NCI-2021-01691
157.
Study of INCB123667 in Subjects With Advanced Solid Tumors
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05238922
Protocol IDs
INCB 123667-101
NCI-2022-03370
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
158.
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT04699188
Protocol IDs
CJDQ443A12101
NCI-2021-01594
159.
Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma
Cancer Type
Cervical Cancer, Unknown Primary
NCT ID
NCT03108495
Protocol IDs
C-145-04
NCI-2017-01051
2016-003447-11
Treatment Sites (1)
160.
Study of Ravulizumab in Pediatric Participants With HSCT-TMA
Cancer Type
Unknown Primary
NCT ID
NCT04557735
Protocol IDs
ALXN1210-TMA-314
NCI-2021-04301
2020-000761-16
161.
Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
Cancer Type
Neuroendocrine Tumor, Pancreatic Cancer, Unknown Primary
NCT ID
NCT05477576
Protocol IDs
RYZ101-301
NCI-2022-06406
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
162.
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
Cancer Type
Unknown Primary
NCT ID
NCT03547973
Protocol IDs
IMMU-132-06 - TROPHY U-01
NCI-2018-03421
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
163.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05382286
Protocol IDs
GS-US-592-6173
NCI-2022-05480
2021-005742-14
jRCT2041220123
KEYNOTE-D19
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
164.
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)
Cancer Type
Brain & Spinal Cord Tumor, Hematopoietic Malignancies, Lymphoma, Unknown Primary
NCT ID
NCT04947319
Protocol IDs
ONO-4059-09
NCI-2021-14196
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
165.
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type
Kidney Cancer, Unknown Primary
NCT ID
NCT05433142
Protocol IDs
XmAb819-01
NCI-2022-05582
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
166.
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05067257
Protocol IDs
RTX-CAP-201
NCI-2022-04731
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
167.
Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04428788
Protocol IDs
CC-94676-PCA-001
NCI-2020-13275
U1111-1251-9174
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
168.
Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04315324
Protocol IDs
S1905
S1905
NCI-2020-00768
169.
Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer, The STABLE-MATES Trial
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT02468024
Protocol IDs
SCCC-02515; STU 022015-069
NCI-2015-01676
Treatment Sites (1)
170.
Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma
Cancer Type
Sarcoma, Unknown Primary
NCT ID
NCT03141684
Protocol IDs
10005
NCI-2016-01040
17-C-007
CC 17-C-0074
17-C-0074
Treatment Sites (1)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
171.
Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04799275
Protocol IDs
S1918
S1918
NCI-2020-01256
172.
NCORP Trial
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT01810913
Protocol IDs
RTOG 1216
NCI-2013-00500
U10CA021661
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
173.
Testing Drug Treatments after CAR T-cell Therapy in Patients with Diffuse Large B-cell Lymphoma That Has Come Back or Not Responded to Treatment
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT05633615
Protocol IDs
S2114
S2114
NCI-2022-07930
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
174.
NCORP Trial
Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT03811015
Protocol IDs
EA3161
EA3161
NCI-2019-00179
Treatment Sites (4)
Atlanta VA Medical Center
Decatur
Scott Edelman
404-728-7680
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
175.
Testing Olaparib and Temozolomide versus the Usual Treatment for Uterine Leiomyosarcoma after Chemotherapy Has Stopped Working
Cancer Type
Sarcoma, Unknown Primary, Uterine Cancer
NCT ID
NCT05432791
Protocol IDs
A092104
A092104
NCI-2022-05065
NCT05432791
176.
NCORP Trial
Testing Pembrolizumab versus Observation in Patients with Merkel Cell Carcinoma after Surgery, STAMP Trial
Cancer Type
Neuroendocrine Tumor, Skin Cancer (Non-Melanoma), Unknown Primary
NCT ID
NCT03712605
Protocol IDs
EA6174
EA6174
NCI-2018-02217
Treatment Sites (1)
179.
Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)
Cancer Type
Hematopoietic Malignancies, Leukemia, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04301076
Protocol IDs
10335
10335
NCI-2020-01535
180.
Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors that have Returned after Previous Treatment
Cancer Type
Brain & Spinal Cord Tumor, Unknown Primary
NCT ID
NCT05432804
Protocol IDs
10505
10505
NCI-2022-05066
PHII-222
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
181.
NCORP Trial
Testing the Addition of Chemotherapy to the Usual Treatment of Ovarian Function Suppression plus Hormonal Therapy in Premenopausal ER-Positive/HER2-Negative Breast Cancer Patients Who Are At High Risk of Cancer Returning, OFSET Trial
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT05879926
Protocol IDs
NRG-BR009
NRG-BR009
NCI-2023-04529
Treatment Sites (1)
Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315
182.
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Cancer Type
Hematopoietic Malignancies, Lymphoma, Non-Hodgkin Lymphoma, Unknown Primary
NCT ID
NCT04803201
Protocol IDs
A051902
A051902
NCI-2021-01380
Treatment Sites (2)
183.
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-small Cell Lung Cancer
Cancer Type
Lung Cancer, Unknown Primary
NCT ID
NCT05624996
Protocol IDs
NRG-LU008
NRG-LU008
NCI-2022-08263
Treatment Sites (1)
184.
Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
Cancer Type
Gynecologic Cancers, Ovarian Cancer, Primary Peritoneal Cancer, Unknown Primary
NCT ID
NCT05276973
Protocol IDs
NRG-GY027
NRG-GY027
NCI-2022-01930
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
185.
Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin
Cancer Type
Head and Neck Cancer, Unknown Primary
NCT ID
NCT04533750
Protocol IDs
NRG-HN008
NRG-HN008
NCI-2020-06481
186.
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer
Cancer Type
Unknown Primary
NCT ID
NCT04628767
Protocol IDs
EA8192
EA8192
NCI-2020-09850
Treatment Sites (2)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
187.
Testing the Addition of Nivolumab to Standard Treatment for Patients with Metastatic or Unresectable Colorectal Cancer that have a BRAF Mutation
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05308446
Protocol IDs
S2107
S2107
NCI-2022-02494
188.
Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment with the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers
Cancer Type
Unknown Primary, Uterine Cancer
NCT ID
NCT05538897
Protocol IDs
NRG-GY028
NRG-GY028
NCI-2022-07505
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
189.
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy after Surgery for Prostate Cancer
Cancer Type
Prostate Cancer , Unknown Primary
NCT ID
NCT04134260
Protocol IDs
NRG-GU008
NRG-GU008
NCI-2019-06838
190.
Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients with Advanced Solid Tumors, The ComBET Trial
Cancer Type
Solid Tumor, Unknown Primary
NCT ID
NCT05327010
Protocol IDs
10486
10486
NCI-2022-02915
Treatment Sites (1)
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
191.
Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and/or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations
Cancer Type
Brain & Spinal Cord Tumor, Cancer-Related Syndrome, Unknown Primary
NCT ID
NCT04201457
Protocol IDs
PBTC-055
PBTC-055
NCI-2019-06216
192.
Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
Cancer Type
Colon/Rectal Cancer, Unknown Primary
NCT ID
NCT05710406
Protocol IDs
A022004
A022004
NCI-2022-09129
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
193.
Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Cancer Type
Neuroendocrine Tumor, Unknown Primary
NCT ID
NCT05040360
Protocol IDs
S2104
S2104
NCI-2021-06619
Treatment Sites (3)
Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411
Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180
194.
Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
Cancer Type
Hematopoietic Malignancies, Leukemia, Unknown Primary
NCT ID
NCT04530565
Protocol IDs
EA9181
EA9181
NCI-2020-06381
Treatment Sites (1)
Augusta University Medical Center
Augusta
Carol Terry
706-721-4430
195.
Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial
Cancer Type
Breast Cancer, Unknown Primary
NCT ID
NCT04852887
Protocol IDs
NRG-BR007
NRG-BR007
NCI-2021-00222